<p>根据 Jennison Associates LLC 最近向证券交易委员会（SEC）提交的 13F 表格，该公司在 2023 年第四季度将其在 Crinetics Pharmaceuticals, Inc.（NASDAQ:CRNX - 免费报告）中的持仓减少了 37.3%。该公司在季度内出售了 763,133 股后，持有 1,281,601 股该公司的股票。根据其最近向证券交易委员会（SEC）提交的文件，Jennison Associates LLC 持有的 Crinetics Pharmaceuticals 约占 1.35%，价值 59,659,000 美元。</p>
<p>其他一些对冲基金也调整了对 CRNX 的持仓。Headlands Technologies LLC 在第二季度购买了 Crinetics Pharmaceuticals 的新头寸，价值约 30,000 美元。Farther Finance Advisors LLC 在第三季度将其在 Crinetics Pharmaceuticals 的持仓增加了 523.7%。Farther Finance Advisors LLC 现在持有 842 股该公司的股票，价值 35,000 美元，此前在上个季度又购买了 707 股。Raymond James Financial Inc.在第二季度购买了 Crinetics Pharmaceuticals 的新头寸，价值 45,000 美元。Covestor Ltd 在第三季度将其在 Crinetics Pharmaceuticals 的持仓增加了 23,983.3%。Covestor Ltd 现在持有 1,445 股该公司的股票，价值 60,000 美元，此前在上个季度又购买了 1,439 股。最后，Abich Financial Wealth Management LLC 在第三季度购买了 Crinetics Pharmaceuticals 的新头寸，价值 68,000 美元。目前 98.51% 的股票由机构投资者持有。</p>
<h2>分析师设定新目标价</h2>
<p>CRNX 已成为几份研究分析师报告的主题。Weiss Ratings 在 4 月 20 日的报告中重新发布了对 Crinetics Pharmaceuticals 股票的 “卖出（d-）” 评级。高盛集团在 1 月 12 日的报告中将 Crinetics Pharmaceuticals 的股票评级从 “中性” 上调至 “买入”，并设定了 67.00 美元的目标价。华尔街 Zen 在 3 月 28 日的报告中将 Crinetics Pharmaceuticals 的股票评级从 “持有” 下调至 “卖出”。摩根士丹利在 1 月 6 日的报告中将 Crinetics Pharmaceuticals 的目标价从 77.00 美元提高到 80.00 美元，并给予该股票 “超配” 评级。最后，Lifesci Capital 在 2 月 13 日的报告中将 Crinetics Pharmaceuticals 的股票评级提升至 “强力买入”。一位研究分析师给予该股票 “强力买入” 评级，八位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，平均目标价为 76.75 美元。</p>
<p><strong>查看我们对 Crinetics Pharmaceuticals 的最新股票分析</strong></p>
<h2>Crinetics Pharmaceuticals 股票上涨 0.9%</h2>
<p>Crinetics Pharmaceuticals 的股票在周五开盘价为 38.78 美元。该公司的市值为 40.6 亿美元，市盈率为-7.85，贝塔值为 0.30。该公司的 50 日移动平均线为 38.52 美元，200 日移动平均线为 43.91 美元。Crinetics Pharmaceuticals, Inc.的 52 周低点为 25.83 美元，52 周高点为 57.99 美元。</p>
<p>Crinetics Pharmaceuticals（NASDAQ:CRNX - 获取免费报告）最近于 2 月 26 日发布了季度财报。该公司报告季度每股收益（EPS）为（1.29 美元），超出分析师一致预期的（1.37 美元）0.08 美元。该季度的收入为 616 万美元，而一致预期为 432 万美元。Crinetics Pharmaceuticals 的净利润率为-6,046.22%，股本回报率为-41.46%。Crinetics Pharmaceuticals 的收入同比增长 NaN%。在去年同期，该公司每股收益为（0.88 美元）。平均而言，股票研究分析师预计 Crinetics Pharmaceuticals, Inc.在当前财年将发布-4.95 的每股收益。</p>
<h2>Crinetics Pharmaceuticals 的内部活动</h2>
<p>在相关消息中，内部人士 Stephen F. Betz 于 3 月 16 日星期一出售了 10,612 股该公司的股票。股票以 37.37 美元的平均价格出售，总交易额为 396,570.44 美元。出售后，内部人士持有 137,101 股该公司的股票，价值 5,123,464.37 美元。这代表其持股减少了 7.18%。该交易已在向证券交易委员会提交的文件中披露，文件可通过此链接获取。此外，首席执行官 Richard Scott Struthers 于 3 月 16 日星期一出售了 21,981 股该公司的股票。股票以 37.37 美元的平均价格出售，总交易额为 821,429.97 美元。出售后，首席执行官直接持有该公司 404,778 股，价值约 15,126,553.86 美元。该交易使其持股减少了 5.15%。该出售的 SEC 文件提供了更多信息。内部人士在上个季度出售了 142,380 股公司股票，价值 5,569,475 美元。目前 4.60% 的股票由内部人士持有。</p>
<h2>Crinetics Pharmaceuticals 简介</h2>
<p>（免费报告）</p>
<p>Crinetics Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化用于罕见内分泌疾病的新型治疗药物。该公司的专有平台利用对激素受体信号传导的洞察，设计小分子候选药物，以解决由激素活动失调引起的疾病。Crinetics 的研究工作集中在靶向生长抑素、抗利尿激素和其他 GPCR 介导的通路，旨在改善患者的便利性和依从性。</p>
<p>该公司的主要产品候选药物 paltusotine（前称 CRN04777）是一种选择性非肽类生长抑素受体 2 型激动剂，正在评估用于治疗肢端肥大症和类癌综合症腹泻。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票，而不是 Crinetics Pharmaceuticals</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Crinetics Pharmaceuticals 吗？</h2>
<p>在考虑 Crinetics Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Crinetics Pharmaceuticals 并不在名单上。</p>
<p>虽然 Crinetics Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CRNX

生物科技 ETF - VanEck Vectors

动态生物技术与基因组 ETF - Invesco

<p>Jennison Associates LLC 已将其在 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) 的持股比例减少了 37.3%，在第四季度出售了 763,133 股。出售后，他们持有 1,281,601 股，估值约为 5966 万美元。其他对冲基金也调整了在 CRNX 的持仓。分析师对该股票的评级不一，目前的平均评级为 “适度买入”，目标价格为 76.75 美元。Crinetics Pharmaceuticals 报告了季度每股亏损 1.29 美元，超出预期，营收为 616 万美元</p>

<p>Jennison Associates LLC reduced its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 37.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,281,601 shares of the company's stock after selling 763,133 shares during the quarter. Jennison Associates LLC owned approximately 1.35% of Crinetics Pharmaceuticals worth $59,659,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>根据 Jennison Associates LLC 最近向证券交易委员会（SEC）提交的 13F 表格，该公司在 2023 年第四季度将其在 Crinetics Pharmaceuticals, Inc.（NASDAQ:CRNX - 免费报告）中的持仓减少了 37.3%。该公司在季度内出售了 763,133 股后，持有 1,281,601 股该公司的股票。根据其最近向证券交易委员会（SEC）提交的文件，Jennison Associates LLC 持有的 Crinetics Pharmaceuticals 约占 1.35%，价值 59,659,000 美元。</p>
</div><p>A number of other hedge funds have also modified their holdings of CRNX. Headlands Technologies LLC bought a new position in shares of Crinetics Pharmaceuticals in the second quarter worth approximately $30,000. Farther Finance Advisors LLC lifted its holdings in shares of Crinetics Pharmaceuticals by 523.7% in the third quarter. Farther Finance Advisors LLC now owns 842 shares of the company's stock worth $35,000 after buying an additional 707 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Crinetics Pharmaceuticals in the second quarter worth $45,000. Covestor Ltd lifted its holdings in shares of Crinetics Pharmaceuticals by 23,983.3% in the third quarter. Covestor Ltd now owns 1,445 shares of the company's stock worth $60,000 after buying an additional 1,439 shares in the last quarter. Finally, Abich Financial Wealth Management LLC purchased a new position in shares of Crinetics Pharmaceuticals in the third quarter worth $68,000. 98.51% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些对冲基金也调整了对 CRNX 的持仓。Headlands Technologies LLC 在第二季度购买了 Crinetics Pharmaceuticals 的新头寸，价值约 30,000 美元。Farther Finance Advisors LLC 在第三季度将其在 Crinetics Pharmaceuticals 的持仓增加了 523.7%。Farther Finance Advisors LLC 现在持有 842 股该公司的股票，价值 35,000 美元，此前在上个季度又购买了 707 股。Raymond James Financial Inc.在第二季度购买了 Crinetics Pharmaceuticals 的新头寸，价值 45,000 美元。Covestor Ltd 在第三季度将其在 Crinetics Pharmaceuticals 的持仓增加了 23,983.3%。Covestor Ltd 现在持有 1,445 股该公司的股票，价值 60,000 美元，此前在上个季度又购买了 1,439 股。最后，Abich Financial Wealth Management LLC 在第三季度购买了 Crinetics Pharmaceuticals 的新头寸，价值 68,000 美元。目前 98.51% 的股票由机构投资者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>CRNX has been the topic of several research analyst reports. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Crinetics Pharmaceuticals in a report on Monday, April 20th. The Goldman Sachs Group raised shares of Crinetics Pharmaceuticals from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $67.00 target price on the stock in a report on Monday, January 12th. Wall Street Zen downgraded shares of Crinetics Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, March 28th. Morgan Stanley boosted their target price on shares of Crinetics Pharmaceuticals from $77.00 to $80.00 and gave the stock an &#34;overweight&#34; rating in a report on Tuesday, January 6th. Finally, Lifesci Capital raised shares of Crinetics Pharmaceuticals to a &#34;strong-buy&#34; rating in a report on Friday, February 13th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $76.75.</p>
<div class="lb-trans"><p>CRNX 已成为几份研究分析师报告的主题。Weiss Ratings 在 4 月 20 日的报告中重新发布了对 Crinetics Pharmaceuticals 股票的 “卖出（d-）” 评级。高盛集团在 1 月 12 日的报告中将 Crinetics Pharmaceuticals 的股票评级从 “中性” 上调至 “买入”，并设定了 67.00 美元的目标价。华尔街 Zen 在 3 月 28 日的报告中将 Crinetics Pharmaceuticals 的股票评级从 “持有” 下调至 “卖出”。摩根士丹利在 1 月 6 日的报告中将 Crinetics Pharmaceuticals 的目标价从 77.00 美元提高到 80.00 美元，并给予该股票 “超配” 评级。最后，Lifesci Capital 在 2 月 13 日的报告中将 Crinetics Pharmaceuticals 的股票评级提升至 “强力买入”。一位研究分析师给予该股票 “强力买入” 评级，八位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，平均目标价为 76.75 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on Crinetics Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Crinetics Pharmaceuticals 的最新股票分析</strong></p>
</div><h2>Crinetics Pharmaceuticals Stock Up 0.9%</h2>
<div class="lb-trans"><h2>Crinetics Pharmaceuticals 股票上涨 0.9%</h2>
</div><p>Crinetics Pharmaceuticals stock opened at $38.78 on Friday. The company has a market cap of $4.06 billion, a price-to-earnings ratio of -7.85 and a beta of 0.30. The firm's fifty day moving average is $38.52 and its 200 day moving average is $43.91. Crinetics Pharmaceuticals, Inc. has a 52-week low of $25.83 and a 52-week high of $57.99.</p>
<div class="lb-trans"><p>Crinetics Pharmaceuticals 的股票在周五开盘价为 38.78 美元。该公司的市值为 40.6 亿美元，市盈率为-7.85，贝塔值为 0.30。该公司的 50 日移动平均线为 38.52 美元，200 日移动平均线为 43.91 美元。Crinetics Pharmaceuticals, Inc.的 52 周低点为 25.83 美元，52 周高点为 57.99 美元。</p>
</div><p>Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported ($1.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.37) by $0.08. The company had revenue of $6.16 million for the quarter, compared to the consensus estimate of $4.32 million. Crinetics Pharmaceuticals had a negative net margin of 6,046.22% and a negative return on equity of 41.46%. Crinetics Pharmaceuticals's revenue was up NaN% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.88) earnings per share. On average, equities research analysts anticipate that Crinetics Pharmaceuticals, Inc. will post -4.95 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Crinetics Pharmaceuticals（NASDAQ:CRNX - 获取免费报告）最近于 2 月 26 日发布了季度财报。该公司报告季度每股收益（EPS）为（1.29 美元），超出分析师一致预期的（1.37 美元）0.08 美元。该季度的收入为 616 万美元，而一致预期为 432 万美元。Crinetics Pharmaceuticals 的净利润率为-6,046.22%，股本回报率为-41.46%。Crinetics Pharmaceuticals 的收入同比增长 NaN%。在去年同期，该公司每股收益为（0.88 美元）。平均而言，股票研究分析师预计 Crinetics Pharmaceuticals, Inc.在当前财年将发布-4.95 的每股收益。</p>
</div><h2>Insider Activity at Crinetics Pharmaceuticals</h2>
<div class="lb-trans"><h2>Crinetics Pharmaceuticals 的内部活动</h2>
</div><p>In related news, insider Stephen F. Betz sold 10,612 shares of the company's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $37.37, for a total transaction of $396,570.44. Following the sale, the insider owned 137,101 shares of the company's stock, valued at $5,123,464.37. This represents a 7.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, CEO Richard Scott Struthers sold 21,981 shares of the company's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $37.37, for a total transaction of $821,429.97. Following the sale, the chief executive officer directly owned 404,778 shares in the company, valued at approximately $15,126,553.86. The trade was a 5.15% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 142,380 shares of company stock valued at $5,569,475 over the last quarter. 4.60% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Stephen F. Betz 于 3 月 16 日星期一出售了 10,612 股该公司的股票。股票以 37.37 美元的平均价格出售，总交易额为 396,570.44 美元。出售后，内部人士持有 137,101 股该公司的股票，价值 5,123,464.37 美元。这代表其持股减少了 7.18%。该交易已在向证券交易委员会提交的文件中披露，文件可通过此链接获取。此外，首席执行官 Richard Scott Struthers 于 3 月 16 日星期一出售了 21,981 股该公司的股票。股票以 37.37 美元的平均价格出售，总交易额为 821,429.97 美元。出售后，首席执行官直接持有该公司 404,778 股，价值约 15,126,553.86 美元。该交易使其持股减少了 5.15%。该出售的 SEC 文件提供了更多信息。内部人士在上个季度出售了 142,380 股公司股票，价值 5,569,475 美元。目前 4.60% 的股票由内部人士持有。</p>
</div><h2>Crinetics Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>Crinetics Pharmaceuticals 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company's proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics' research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.</p>
<div class="lb-trans"><p>Crinetics Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化用于罕见内分泌疾病的新型治疗药物。该公司的专有平台利用对激素受体信号传导的洞察，设计小分子候选药物，以解决由激素活动失调引起的疾病。Crinetics 的研究工作集中在靶向生长抑素、抗利尿激素和其他 GPCR 介导的通路，旨在改善患者的便利性和依从性。</p>
</div><p>The company's lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.</p>
<div class="lb-trans"><p>该公司的主要产品候选药物 paltusotine（前称 CRN04777）是一种选择性非肽类生长抑素受体 2 型激动剂，正在评估用于治疗肢端肥大症和类癌综合症腹泻。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Crinetics Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Crinetics Pharmaceuticals</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CRNX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Crinetics Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Crinetics Pharmaceuticals 吗？</h2>
</div><p>Before you consider Crinetics Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Crinetics Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crinetics Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Crinetics Pharmaceuticals 并不在名单上。</p>
</div><p>While Crinetics Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Crinetics Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Jennison Associates LLC Sells 763,133 Shares of Crinetics Pharmaceuticals, Inc. $CRNX

Market Beat

Crinetics Pharmaceuticals

纽交所高增长板生物技术指数 ETF - First Trust

美国制药 ETF - iShares

医药突破 ETF - ALPS

标普全球医疗股指数 ETF - iShares

医疗业 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

医疗业 ETF - Vanguard

标普生物技术 3 倍做多 - Direxion

基因改革 ETF - ARK

瑞杰金融

高盛

摩根士丹利

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

GS Hldg R

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Jennison Associates LLC 出售了 763,133 股 Crinetics Pharmaceuticals, Inc. 的股票 $CRNX